Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_4437_Библиотеки_им_академика_М_И_Перельмана
.pdf
396
M. Sakr
Evaluation by computed tomography. Arch
Otolaryngol. 1984;110(7):443–7.
177. Som PM. Lymph nodes of the neck. Radiology.
1987;165(3):593–600.
178. Mancuso AA, Maceri D, Rice D, Hanafee W.CT
of cervical lymph node cancer. Am J Roentgenol.
1981;136(2):381–5.
179. Wu CW, Dionigi G, Lee KW, Hsiao PJ, Paul Shin
MC, Tsai KB, etal. Calcications in thyroid nodules identied on preoperative computed tomography: patterns and clinical signicance. Surgery.
2011;10:12–9.
180. Deandrea M, Mormile A, Veglio M, et al. Fineneedle aspiration biopsy of the thyroid: comparison
between thyroid palpation and ultrasonography.
Endocr Pract. 2002;8:282–6.
181. Frable MA, Frable WJ.Fine-needle aspiration biopsy
revisited. Laryngoscope. 1982;92(12):1414–8.
182. Engzell U, Jakobbsen PA, Zajicek J. Aspiration
biopsy of metastatic carcinoma in lymph nodes of
the neck. A review of 1101 consecutive cases. Acta
Otolaryngol. 1972;72:138–47.
183. Russ JE, Scanlon EF, Christ MA. Aspiration
cytology of head and neck masses. Am J Surg.
1978;136(3):342–7.
184. Gupta SK, Data TK, Waikato M, Gupta BD, Stalwart
BL, Waikato BK. Evaluation of ne needle aspiration biopsy technique in the diagnosis of tumors.
Indian J Cancer. 1975;12(3):257–67.
185. Kline TS, Neal HS.Needle aspiration biopsy: a critical appraisal. Eight years and 3267 specimens later.
JAMA. 1978;239(1):36–9.
186. Malabar D, Jacopo I, Startup K, Gupta OP, Jain AP,
Pole VW.A clinical evaluation of ne needle aspiration cytology in the diagnosis of lymphadenopathy.
Int J Tub. 1991;38:17–9.
187. Pundit AA, Candies FP, Khubchandani SR.Fine needle aspiration cytology of lymph nodes. J Postgrad
Med. 1987;33(3):134–6.
188. Renshaw AA. Sensitivity of ne-needle aspiration
for papillary carcinoma of the thyroid correlates with
tumor size. Diagn Cytopathol. 2011;39(7):471–4.
189. Zada B, Anwar K, Malik SA, Niamatullah KN,
Salam F.Anatomical relationship between recurrent
laryngeal nerve and inferior thyroid artery in thyroidectomy patients. J Ayub Med Coll Abbottabad.
2014;26(3):380–3.
190. Yuan Z, Quan J, Yunxiao Z, Jian C, Zhu H.Contrastenhanced ultrasound in the diagnosis of solitary thyroid nodules. J Cancer Res Ther. 2015;11(1):41–5.
191. Al-Shaikh A, Ngan B, Daneman A, Daneman
D.Fine-needle aspiration biopsy in the management
of thyroid nodules in children and adolescents. J
Pediatr. 2001;138(1):140–2.
192. Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Am J Clin Pathol (AJCP).
2009;132:658–65.
193. Falk SA, McCaffrey TV. Management of recurrent
laryngeal nerve in suspected and proven thyroid cancer. Otolaryngol Head Neck Surg. 1995;113:42–8.
194. Cernea CR, Ferraz AR, Monteiro S, et al.
Identication of the external branch of the superior
laryngeal nerve during thyroidectomy. Am J Surg.
1992;164:634–9.
195. Olson JA Jr, DeBenedetti MK, Baumann DS, Wells
SA Jr. Parathyroid autotransplantation during thyroidectomy. Results of long-term follow-up. Ann
Surg. 1996;223:472–80.
196. El-Sharaky M, Khalil M, Sharaky O, Sakr M, Fadaly
G, El-Hammadi H, Moussa M.Assessment of parathyroid autotransplantation for preservation of parathyroid function after total thyroidectomy. Head
Neck. 2003;25(10):799–807.
197. Cheah WK, Arici C, Ituarte PH, Siperstein AE, Duh
QY, Clark OH.Complications of neck dissection for
thyroid cancer. World J Surg. 2002;26:1013–6.
198. Ozaki O, Ito K, Kobayashi K, Suzuki A, Manabe
Y. Modied neck dissection for patients with nonadvanced, differentiated carcinoma of the thyroid.
World J Surg. 1988;12(6):825–9.
199. Noguchi M, Kumaki T, Taniya T, Miyazaki
I. Bilateral cervical lymph node metastases in
well-differentiated thyroid cancer. Arch Surg.
1990;125(6):804–6.
200. Mazzaferri EL, Young RL.Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med. 1981;70(3):511–8.
201. Cady B.Surgery of thyroid cancer. World J Surg.
1981;5(1):3–14.
202. McGregor GI, Luoma A, Jackson SM. Lymph
node metastases from well-differentiated thyroid cancer. A clinical review. Am J Surg.
1985;149(5):610–2.
203. Clark OH, Duh QY.Thyroid cancer. Med Clin North
Am. 1991;75(1):211–34.
204. Lee KY, Lore JM Jr. The treatment of metastatic thyroid disease. Otolaryngol Clin N Am.
1990;23:475–93.
205. Simpson WJ, McKinney SE, Carruthers JS,
Gospodarowicz MK, Sutcliffe SB, Panzarella
T. Papillary and follicular thyroid cancer.
Prognostic factors in 1578 patients. Am J Med.
1987;83(3):479–88.
206. Scheumann GFW, Gimm O, Wegener G,
Hundeshagen H, Dralle H. Prognostic signicance
and surgical management of locoregional lymph
node metastases in papillary thyroid cancer. World J
Surg. 1994;18(4):559–67.
207. Rosai J, Zampi G, Carcangiu ML. Papillary carcinoma of the thyroid. A discussion of its several
morphologic expressions, with particular emphasis on the follicular variant. Am J Surg Pathol.
1983;7:809–17.
208. Schwartz SI, Brunicardi F, Dana A, Timothy B,
David D, John H, etal. Thyroid and parathyroid. In:
Brunicardi F, Dana A, Timothy B, David D, John
H, Jeffrey M, editors. Principles of surgery. 9th ed.
McGraw-Hill; 2009. p.1344–88.
209. Cady B, Rossi R, Silverman M, Wool M. Further
evidence of the validity of risk group denition
t.me/Dr_Mouayyad_AlbtousH
13 Malignant Thyroid Disease
397
in differentiated thyroid carcinoma. Surgery.
1985;98(6):1171–8.
210. Tubiana M, Schlumberger M, Rougier P, Laplanche
A, Benhamou E, Gardet P, et al. Long-term results
and prognostic factors in patients with differentiated
thyroid carcinoma. Cancer. 1985;55(4):794–804.
211. Hay ID, Taylor WF, McConahey WM.A prognostic score for predicting outcome in papillary thyroid
carcinoma. Endocrinology. 1986;119:1–15.
212. Kelemen PR, Van Herle AJ, Giuliano AE.Sentinel
lymphadenectomy in thyroid malignant neoplasms.
Arch Surg. 1998;133(3):288–92.
213. Mazzaferri EL.Papillary thyroid carcinoma: factors
inuencing prognosis and current therapy. Semin
Oncol. 1987;14(3):315–32.
214. LiVolsi VA, Baloch ZW.Follicular neoplasms of the
thyroid: view, biases, and experiences. Adv Anat
Pathol. 2004;11(6):279–87.
215. Williams ED.Guest editorial: two proposals regarding the terminology of thyroid tumors. Int J Surg
Pathol. 2000;8(3):181–3.
216. Carcangiu ML.Minimally invasive follicular carcinoma. Endocr Pathol. 1997;8(3):231–4.
217. Kahn NF, Perzin KH. Follicular carcinoma of the
thyroid: an evaluation of the histologic criteria used
for diagnosis. Pathol Annu. 1983;18(1):221–53.
218. Franssila KO, Ackerman LV, Brown CL, Hedinger
CE. Follicular carcinoma. Semin Diagn Pathol.
1985;2(2):101–22.
219. LiVolsi VA, Asa SL.The demise of follicular carcinoma of the thyroid gland. Thyroid. 1994;4(2):233–6.
220. Randolph GW. The importance of preoperative
laryngoscopy in patients undergoing thyroidectomy:
voice, vocal cord function, and the preoperative
detection of invasive thyroid malignancy. Surgery.
2006;139:363–4.
221. McHenry CR, Phitayakorn R. Follicular adenoma
and carcinoma of the thyroid gland. Oncologist.
2011;16(5):585–93.
222. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit
JW, Wiersinga W. European Thyroid cancer taskforce. European consensus for the management
of patients with differentiated thyroid carcinoma
of the follicular epithelium. Eur J Endocrinol.
2006;154(6):787–803.
223. Thompson LD, Wieneke JA, Paal E, Frommelt RA,
Adair CF, Heffess CS.A clinicopathologic study of
minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature.
Cancer. 2001;91(3):505–24.
224. McLeod MK, Thompson NW. Hürthle cell neoplasms of the thyroid. Otolaryn Clin North Am.
1990;23:441–52.
225. Goldman ND, Coniglio JU, Falk SA.Thyroid cancers I: papillary, follicular, and Hürthle cell. Otolaryn
Clin North Am. 1996;30:593–609.
226. Chen H, Udelsman R.Hürthle cell adenoma and carcinoma. In: Clark OH, Duh QY, editors. Textbook
of endocrine Surgery. 1st ed. Philadelphia, PA: WB
Saunders Co.; 1997. p.103–7.
227. Cooper DS, Schneyer CR. Follicular and Hürthle
cell carcinoma of the thyroid. Endocrinol Metab
Clin N Am. 1990;19:577–91.
228. Pisanu A, Di Chiara B, Reccia I, Uccheddu
A. Oncocytic cell tumors of the thyroid: factors
predicting malignancy and inuencing prognosis,
treatment decisions, and outcomes. World J Surg.
2010;34(4):836–43.
229. Lee KH, Shin JH, Ko ES, Hahn SY, Kim JS, Kim
JH, et al. Predictive factors of malignancy in
patients with cytologically suspicious for Hurthle
cell neoplasm of thyroid nodules. Int J Surg.
2013;11(9):898–902.
230. Zhang YW, Greenblatt DY, Repplinger D, Bargren
A, Adler JT, Chen H. Factors that predict malignancy in Hürthle cell neoplasms of the thyroid. J
Surg Res. 2008;144(2):371–2.
231. Mills SC, Haq M, Smellie WJ, Harmer C.Hurthle
cell carcinoma of the thyroid: retrospective review
of 62 patients treated at the Royal Marsden
Hospital between 1946 and 2003. Eur J Surg Oncol.
2009;35(3):230–4.
232. Stojadinovic A, Ghossein RA, Hoos A, Urist MJ,
Spiro RH, Shah JP, et al. Hurthle cell carcinoma:
a critical histopathologic appraisal. J Clin Oncol.
2001;19(10):2616–25.
233. Wakely PE Jr. Oncocytic and oncocyte-like
lesions of the head and neck. Ann Diagn Pathol.
2008;12(3):222–30.
234. Gonzalez-Campora R, Herrero-Zapatero A,
Lerma E, Sanchez F, Galera H. Hurthle cell and
mitochondrion- rich cell tumors. A clinicopathologic
study. Cancer. 1986;57(6):1154–63.
235. Baloch ZW, LiVolsi VA. Oncocytic lesions of
the neuroendocrine system. Semin Diagn Pathol.
1999;16(2):190–9.
236. Cibas ES, Ali SZ. The Bethesda system for
reporting thyroid cytopathology. Thyroid.
2009;19(11):1159–65.
237. Nguyen GK, Ginsberg J, Crockford PM. Fine
needle aspiration biopsy cytology of the thyroid.
Its value and limitations in the diagnosis and treatment of solitary thyroid nodules. Pathol Annu.
1991;26(1):63–91.
238. Gharib H, Goeller JR, Zinsmeister AR, Grant CS,
Heerden JA. Fine-needle aspiration biopsy of the
thyroid. The problem of suspicious cytologic ndings. Ann Intern Med. 1984;101:25–8.
239. Roh MH, Jo VY, Stelow EB, et al. The predictive
value of the ne-needle aspiration diagnosis “suspicious for a FNHCT” in patients with Hashimoto thyroiditis. Am J Clin Pathol. 2012;120:73–86.
240. Stankov K, Romeo G.Oxyphilic carcinoma of the
thyroid gland. Arch Oncol. 2003;11(2):81–9.
241. Melck A, Bugis S, Baliski C, Irvine R, Anderson DW,
Wilkins G, etal. Hemithyroidectomy: the preferred
initial surgical approach for management of Hurthle
cell neoplasm. Am J Surg. 2006;191(5):593–7.
242. Chen H, Nicol TL, Zeiger MA, Dooley WC,
Ladenson PW, Cooper DS, et al. Hurthle cell
t.me/Dr_Mouayyad_AlbtousH
398
M. Sakr
neoplasms of the thyroid: are there factors predictive
of malignancy? Ann Surg. 1998;227(4):542–6.
243. Pisanu A, Sias L, Uccheddu A. Factors predicting malignancy of Hürthle cell tumors of the thyroid: inuence on surgical treatment. World J Surg.
2004;28(8):761–5.
244. Haugen BR, Alexander EK, Bible KC, Doherty GM,
Mandel SJ, Nikiforov YE, et al. 2015 American
Thyroid Association management guidelines for
adult patients with thyroid nodules and differentiated
thyroid cancer: the American Thyroid Association
guidelines task force on Thyroid nodules and differentiated Thyroid cancer. Thyroid. 2016;26(1):1–133.
245. Pu RT, Yang J, Wasserman PG, Grifth KA, Michael
CW. Does Hurthle cell lesion/neoplasm predict
malignancy more than follicular lesion/neoplasm on
thyroid ne-needle aspiration? Diagn Cytopathol.
2006;34(5):330–4.
246. Stojadinovic A, Hoos A, Ghossein RA, Urist
MJ, Leung DH, Spiro RH, et al. Hurthle cell carcinoma: a 60-year experience. Ann Surg Oncol.
2002;9(2):197–203.
247. Auger M.Hurthle cells in ne-needle aspirates of
the thyroid: a review of their diagnostic criteria and
signicance. Cancer Cytopathol. 2014;122:241–9.
248. Azadian A, Rosen IB, Walsh PG, Asa
SL.Managemen considerations in Hürthle cell carcinoma. Surgery. 1995;118(4):711–5.
249. Hudak K, Mazeh H, Sippel RS, Chen H.Hürthle cell
metaplasia on ne-needle aspiration biopsy is not by
itself an indication for thyroid surgery. Am J Surg.
2012;203(3):287–91.
250. Kauffmann PR, Dejax C, de Latour M, Dauplat
J.The meaning and predictivity of Hürthle cells in
ne needle aspiration cytology for thyroid nodular
disease. Eur J Surg Oncol. 2004;30(7):786–9.
251. Kroeker T, Prisman E, Shah M, MacMillan C,
Freeman JL. Hurthle cell lesions-a retrospective
review of nal surgical pathology. Thyroid Disord
Ther. 2014;3(155):2.
252. Parikh PP, Allan BJ, Lew JI. Surgeon-performed
ultrasound predictors of malignancy in patients with
Hürthle cell neoplasms of the thyroid. J Surg Res.
2013;184(1):247–52.
253. McHenry CR, Thomas SR, Slusarczyk SJ, Khiyami
A.Follicular or Hu rthle cell neoplasm of the thyroid: can clinical factors be used to predict carcinoma and determine extent of thyroidectomy?
Surgery. 1999;126(4):798–804.
254. Haigh PI, Urbach DR.The treatment and prognosis
of Hürthle cell follicular thyroid carcinoma compared with its non-Hürthle cell counterpart. Surgery.
2005;138(6):1152–8.
255. Paunovic I, Krgovic K, Tatic S, Diklic A, Zivaljevic
V, Kalezic N, etal. Surgery for thyroid Hürthle cell
tumours—a single institution experience. Eur J Surg
Oncol. 2006;32(4):458–61.
256. Khaf A, Khaf RA, Attie JN. Hürthle cell carcinoma: a malignancy of low-grade potential. Head
Neck. 1999;21(6):506–11.
257. Sippel RS, Elaraj DM, Khanafshar E, Zarnegar R,
Kebebew E, Duh QY, et al. Tumor size predicts
malignant potential in Hurthle cell neoplasms of the
thyroid. World J Surg. 2008;32(5):702–7.
258. Zhang Y, Greenblatt D, Repplinger D, Bargren A,
Adler JT, Sippel RS, etal. Older age and larger tumor
size predict malignancy in Hürthle cell neoplasms of
the thyroid. Ann Surg Oncol. 2008;15(10):2842–6.
259. Kushchayeva Y, Duh Q-Y, Kebebew E, D’Avanzo A,
Clark OH.Comparison of clinical characteristics at
diagnosis and during follow-up in 118 patients with
Hurthle cell or follicular thyroid cancer. Am J Surg.
2008;195(4):457–62.
260. Carcangiu ML, Bianchi S, Savino D, Voynick IM,
Rosai J.Follicular Hurthle cell tumors of the thyroid
gland. Cancer. 1991;68(9):1944–53.
261. Sanders LE, Silverman M. Follicular and Hürthle
cell carcinoma: predicting outcome and directing
therapy. Surgery. 1998;124(6):967–74.
262. Chao T-C, Lin J-D, ChenM-F. Surgical treatment
of Hurthle cell tumors of the thyroid. World J Surg.
2005;29(2):164–8.
263. Yutan E, Clark O.Hürthle cell carcinoma. Curr Treat
Options in Oncol. 2001;2(4):331–5.
264. Lopez-Penabad L, Chiu AC, Hoff AO, Schultz P,
Gaztambide S, Ordoñez NG, et al. Prognostic factors in patients with Hurthle cell neoplasms of the
thyroid. Cancer. 2003;97(5):1186–94.
265. Haddad RI, Bischoff L, Ball D, Bernet V, Blomain
E, Busaidy NL, et al. Thyroid carcinoma, version
2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2022;20(8):925–51.
266. Are C, Shaha AR.Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment
approaches. Ann Surg Oncol. 2006;13(4):453–64.
267. Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner
MD, Quivey JM, et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant
chemotherapy and irradiation is associated with prolonged survival. Cancer. 2001;91(12):2335–42.
268. Kebebew E, Greenspan FS, Clark OH, Woeber
KA, McMillan A. Anaplastic thyroid carcinoma:
treatment outcome and prognostic factors. Cancer.
2005;103(7):1330–5.
269. Chang TC, Liaw KY, Kuo SH, Chang CC, Chen
FW. Anaplastic thyroid carcinoma: review of 24
cases, with emphasis on cytodiagnosis and leukocytosis. Taiwan Yi Xue Hui Za Zhi. 1989;88(6):551–6.
270. Berry B, MacFarlane J, Chan N.Osteoclastomalike
anaplastic carcinoma of the thyroid. Diagnosis
by ne needle aspiration cytology. Acta Cytol.
1990;34(2):248–50.
271. Carcangiu M, Steeper T, Zampi G, Rosai J,
Anaplastic thyroid carcinoma. A study of 70 cases.
Am J Clin Pathol. 1985;83:135–58.
272. Hurlimann J, Gardiol D, Scazziga
B. Immunohistology of anaplastic thyroid carcinoma. Histopathology. 1987;11:567.
273. Ito T, Seyama T, Mizuno T, et al. Unique association of p53 mutations with undifferentiated but not
t.me/Dr_Mouayyad_AlbtousH
13 Malignant Thyroid Disease
399
with differentiated carcinomas of the thyroid gland.
Cancer Res. 1992;52:1369–71.
274. Dobashi Y, Sugimura H, Sakamoto A, Mernyei
M, Mori M, Oyama T, et al. Stepwise participation of p53 gene mutation during dedifferentiation
of human thyroid carcinomas. Diagn Mol Pathol.
1994;3:9–14.
275. Ito K, Hanamura T, Murayama K, Okada T, Watanabe
T, Harada M, etal. Multimodality therapeutic outcomes in anaplastic thyroid carcinoma: improved
survival in subgroups of patients with localized primary tumors. Head Neck. 2012;34(2):230–7.
276. Yau T, Lo CY, Epstein RJ, Lam AK, Wan KY,
Lang BH. Treatment outcomes in anaplastic thyroid carcinoma: survival improvement in young
patients with localized disease treated by combination of surgery and radiotherapy. Ann Surg Oncol.
2008;15(9):2500–5.
277. McLarnon A. Thyroid cancer: Pazopanib alone is
not effective against anaplastic thyroid cancer. Nat
Rev Endocrinol. 2012;8(10):565–9.
278. Polistena A, Monacelli M, Lucchini R, Triola R,
Conti C, Avenia S, etal. The role of surgery in the
treatment of thyroid anaplastic carcinoma in the
elderly. Int J Surg. 2014;12:176–81.
279. Xu H, Shen Z, Xiao J, Yang Y, Huang W, Zhou Z,
etal. Acetylcholinesterase over-expression mediated
by oncolytic adenovirus exhibited potent anti-tumor
effect. BMC Cancer. 2014;14:668–73.
280. Lee DY, Won JK, Lee SH, Park do J, Jung KC, Sung
MW, et al. Changes of Clinicopathologic characteristics and survival outcomes of Anaplastic and
poorly differentiated Thyroid carcinoma. Thyroid.
2016;26(3):404–13.
281. Sugitani I, Miyauchi A, Sugino K, Okamoto T,
Yoshida A, Suzuki S. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma:
ATC research consortium of Japan cohort study of
677 patients. World J Surg. 2012;36(6):1247–54.
282. Brown RF, Ducic Y. Aggressive surgical resection
of anaplastic thyroid carcinoma may provide longterm survival in selected patients. Otolaryngol-Head
Neck Surg. 2013;148(4):564–71.
283. Smallridge RC.Approach to the patient with anaplastic thyroid carcinoma. J Clin Endocrinol Metab.
2012;97(8):2566–72.
284. Tennvall J, Lundell G, Wahlberg P, Bergenfelz A,
Grimelius L, Akerman M, etal. Anaplastic thyroid
carcinoma: three protocols combining doxorubicin,
hyperfractionated radiotherapy and surgery. Brit J
Cancer. 2002;86(12):1848–53.
285. Glaser SM, Mandish SF, Gill BS, Balasubramani
GK, Clump DA, Beriwal S.Anaplastic thyroid cancer: prognostic factors, patterns of care, and overall
survival. Head Neck. 2016;38(1):E2083–90.
286. Pushkarev VM, Starenki DV, Saenko VA, Pushkarev
VV, Kovzun OI, Tronko MD, et al. Differential
effects of low and high doses of Taxol in anaplastic
thyroid cancer cells: possible implication of the Pin1
prolyl isomerase. Exp Oncol. 2008;30(3):190–4.
287. Heron DE, Karimpour S, Grigsby PW. Anaplastic
thyroid carcinoma: comparison of conventional
radiotherapy and hyperfractionation chemoradiotherapy in two groups. Am J Clin Oncol.
2002;25(5):442–6.
288. Ito T, Seyama T, Iwamoto KS, Hayashi T, Mizuno
T, Tsuyama N, et al. In vitro irradiation is able to
cause RET oncogene rearrangement. Cancer Res.
1993;53(13):2940–3.
289. Fagin JA. Genetics of papillary thyroid cancer initiation: implications for therapy. Trans Am Clin
Climatol Assoc. 2005;116:259–69.
290. Liu TR, Xiao ZW, Xu HN, Long Z, Wei FQ, Zhuang
SM, Sun XM, Xie LE, Mu JS, Yang AK, Zhang GP,
Fan Y.Treatment and prognosis of anaplastic thyroid
carcinoma: a clinical study of 50 cases. PLoS One.
2016;11(10):e0164840.
291. Busnardo B, Daniele O, Pelizzo MR, Mazzarotto
R, Nacamulli D, Devido D, etal. A multimodality
therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients. J Endocrinol Investig.
2000;23(11):755–61.
292. Kim J, Leeper R.Treatment of anaplastic giant and
spindle cell carcinoma of the thyroid gland with
combination adriamycin and radiation therapy. A
new approach. Cancer. 1983;52:954–7.
293. Venkatesh YS, Ordonez NG, Schultz PN, Hickey
RC, Goepfert H, Samaan NA.Anaplastic carcinoma
of the thyroid. A clinicopathologic study of 121
cases. Cancer. 1990;66:321–30.
294. Sun C, Li Q, Hu Z, He J, Li C, Li G, etal. Treatment
and prognosis of anaplastic thyroid carcinoma:
experience from a single institution in China. PLoS
One. 2013;8(11):e80011.
295. Lo CY, Lam KY, Wan KY.Anaplastic carcinoma of
the thyroid. Am J Surg. 1999;177(4):337–9.
296. Kim TY, Kim KW, Jung TS, Kim JM, Kim SW,
Chung KW, et al. Prognostic factors for Korean
patients with anaplastic thyroid carcinoma. Head
Neck. 2007;29(8):765–72.
297. Danese D, Sciacchitano S, Farsetti A, Andreoli M,
Pontecorvi A.Diagnostic accuracy of conventional
versus sonography-guided ne-needle aspiration
biopsy of thyroid nodules. Thyroid. 1998;8:15–21.
298. Moley JF. Medullary thyroid carcinoma. In:
Prinz RA, Staren ED, editors. Endcorine surgery. Georgetown, TX: LANDES Bioscience
Vademacum; 2000. p.69–79.
299. Ogilvie JB, Kebebew E. Indication and timing of
thyroid surgery for patients with hereditary medullary thyroid cancer syndromes. J Natl Compr Cancer
Netw. 2006;4:139–47.
300. Cohen EG, Shaha AR, Rinaldo A, Devaney KO,
Ferlito A. Medullary thyroid carcinoma. Acta
Otolaryngol. 2004;124(5):544–57.
301. Abrosimov A. Histologic and immunohistochemical characterization of medullary thyroid carcinoma.
Arkh Patol. 1996;58(4):43–8.
302. Association of Clinical Biochemistry, British
Thyroid Association, British Thyroid Foundation.
t.me/Dr_Mouayyad_AlbtousH
400
M. Sakr
UK guidelines for the use of thyroid function tests.
London: ACB; 2006.
303. Ukkat J, Gimm O, Brauckhoff M, Bilkenroth U,
Dralle H. Single center experience in primary surgery for medullary thyroid carcinoma. World J Surg.
2004;28:1271–4.
304. de Groot JW, Links TP, Plukker JT, Lips CJ, Hofstra
RM.RET as a diagnostic and therapeutic target in
sporadic and hereditary endocrine tumors. Endocr
Rev. 2006;27:535–60.
305. Elisei R, Bottici V, Luchetti F, etal. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer:
experience in 10,864 patients with nodular thyroid
disorders. J Clin Endocrinol Metab. 2004;89:163–8.
306. Gittoes NJ, Miller MR, Daykin J, Sheppard MC,
Franklyn JA.Upper airways obstruction in 153 consecutive patients presenting with thyroid enlargement. BMJ. 1996;312:484.
307. Moley JF, Dilley WG, DeBenedetti MK.Improved
results of cervical reoperation for medullary thyroid
carcinoma. Ann Surg. 1997;225:734–43.
308. Samaan N, Schultz P, Hickey R.Medullary thyroid
carcinoma: prognosis of familial versus nonfamilial
disease and the results of radiotherapy. Hormone
Metab Res. 1989;21:20–5.
309. Farndon JR, Leight GS, Dilley WG, Baylin SB,
Smallridge RC, Harrison TS, et al. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg.
1986;73:278–81.
310. Samaan NA, Draznin MB, Halpin RE, Bloss
RS, Hawkins E, Lewis RA. Multiple endocrine
syndrome type IIB in early childhood. Cancer.
1991;68:1832–4.
311. Sakamoto A, Kasai N, Sugano H. Poorly differentiated carcinoma of the thyroid. Cancer.
1983;52:1849–55.
312. Carcangiu ML, Zampi G, Rosai J.Poorly differentiated (“insular”) thyroid carcinoma. A reinterpretation of Langhans’ “wuchernde struma”. Am J Surg
Pathol. 1984;8:655–68.
313. Pilotti S, Collini P, Mariani L, et al. Insular carcinoma: a distinct de novo entity among follicular
carcinomas of the thyroid cancer. Am J Surg Pathol.
1997;21:1466–73.
314. Ashfaq R, Vuitch F, Delgado R, Albores-Saavedra
J. Papillary and follicular thyroid carcinomas with
an insular component. Cancer. 1994;73:416–23.
315. Volante M, Collini P, Nikiforov YE, Sakamoto
A, Kakudo K, Katoh R, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the
use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol.
2007;31(8):1256–64.
316. Asioli S, Erickson LA, Righi A, Jin L, Volante M,
Jenkins S, et al. Poorly differentiated carcinoma
of the thyroid: validation of the Turin proposal
and analysis of IMP3 expression. Mod Pathol.
2010;23(9):1269–78.
317. Takeuchi Y, Daa T, Kashima K, Yokoyama S,
Nakayama I, Noguchi S. Mutation of p53 in thyroid carcinoma with an insular component. Thyroid.
1999;9:377–81.
318. Killeen RM, Barnes L, Waston CG, Marsh WL,
Chase DW, Schuller DE. Poorly differentiated
(“insular”) thyroid carcinoma. Arch Otol Head Neck
Surg. 1990;116:1082–6.
319. Lam KY, Lo CY, Chan KW, Wan KY. Insular and
anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review
of the signicance of p53 and p21. Ann Surg.
2000;321:329–38.
320. Matias-Guiu X, Villanueva A, Cuatrecasas M,
Capella G, De Leiva A, Prat J. P53 in a thyroid
follicular carcinoma with foci of poorly differentiated and anaplastic carcinoma. Pathol Res Pract.
1996;192:1242–9.
321. Russo D, Tumino S, Arturi F, Vigneri P, Grasso
G, Pontecorvi A, et al. Detection of an activating
mutation of the thyrotropin receptor in a case of an
autonomously hyperfunctioning thyroid insular carcinoma. J Clin Endocrinol Metab. 1997;82:735–8.
322. Albores-Saavedra J, Housini I, Vuitch F, Snyder
WH III.Macrofollicular variant of papillary thyroid
carcinoma with minor insular component. Cancer.
1997;80:1110–6.
323. Donohue JH, Golden SD, Miller TR, Abele JS,
Clark OH. Do the prognoses of papillary and follicular thyroid carcinomas differ? Am J Surg.
1983;148:168–73.
324. Cady B, Rossi R.An expanded view of risk-group
denition in differentiated thyroid carcinoma.
Surgery. 1988;104:947–53.
325. Justin EP, Seabold JE, Robinson RA, Wlaker WP,
Gurll NJ, Hawes DR.Insular carcinoma: a distinct
thyroid carcinoma with associated iodine-131 localization. J Nucl Med. 1991;32:1358–63.
326. Flynn SD, Formann BH, Stewart AF, Kinder
BK.Poorly differentiated (insular) carcinoma of the
thyroid gland: an aggressive subset of differentiated
thyroid neoplasms. Surgery. 1988;104:963–70.
327. Papotti M, Botto Micca F, Favero A, Palestini N,
Bussolati G. Poorly differentiated thyroid carcinomas with primordial cell component. Am J Surg
Pathol. 1993;17:291–301.
328. Auge B, Rodier JF, Pusel J, Janser JC. Le carcinome insulaire de la thyroide. A propos d’un cas
avec revue de la litte’rature. Arch Anat Cytol Pathol.
1993;41:124–8.
329. Albareda M, Puig-Domingo M, Wengrowicz S,
Soldevila J, Matias-Guiu X, Caballero A, et al.
Clinical forms of presentation and evolution of diffuse sclerosing variant of papillary carcinoma and
insular variant of follicular carcinoma of the thyroid.
Thyroid. 1988;8:385–91.
330. Limbert E, Soares J, Bothelho L, Sobrino-Simoes
M.Insular thyroid carcinoma in clinicopathological
study of 12 cases. In: Jafol C, Milhaud G, editors.
t.me/Dr_Mouayyad_AlbtousH
13 Malignant Thyroid Disease
401
Thyroid cancer. NewYork: Elsevier Science; 1985.
p.317–9.
331. Burman KD, Ringel MD, Wartofsky L. Unusual
types of thyroid neoplasms. Endocrinol Metab Clin
N Am. 1996;25:49–68.
332. Franc B, Ledent C, De Saint-Maur PP, Parmentier
M. Thyroid insular carcinoma. Arch Anat Cytol
Pathol. 1998;46:63–78.
333. Mizukami Y, Nonomura A, Michigishi T. Poorly
differentiated (“insular”) carcinoma of the thyroid.
Pathol Int. 1995;45:663–8.
334. Palestini N, Papotti M, Durando R, Fortunato
MA. Poorly differentiated “insular” carcinoma
of the thyroid: long-term survival. Minerva Chir.
1993;48:1301–5.
335. Rodriguez JM, Parrilla P, Moreno A, Sola J, Pinero
A, Ortiz S, et al. Insular carcinoma: an infrequent subtype of thyroid cancer. J Am Coll Surg.
1998;187:503–8.
336. Sasaki A, Daa T, Kashima K, Yokoyama S,
Nakayama I, Noguchi S. Insular component as
a risk factor of thyroid carcinoma. Pathol Int.
1996;46:939–46.
337. Hassoun AAK, Hay ID, Goellner JR, Zimmerman
D. Insular thyroid carcinoma in adolescents: a
potentially lethal endocrine malignancy. Cancer.
1997;79:1044–8.
338. Van den Brekel MW, Hekkenberg RJ, Asa SL,
Tomlinson G, Rosen IB, Freeman JL. Prognostic
features in tall cell papillary carcinoma and insular
thyroid carcinoma. Laryngoscope. 1997;107:254–9.
339. Machens A, Hinze R, Lautenschlager C, Dralle
H.Multivariate analysis of clinicopathologic parameters for the insular subtype of differentiated thyroid
carcinoma. Arch Surg. 2001;136:941–4.
340. Renshaw AA, Pinnar N.Comparison of thyroid neneedle aspiration and core needle biopsy. Am J Clin
Pathol. 2007;128:370–4.
341. Bouhabel S, Payne RJ, Mlynarek A, Hier M, Caglar
D, Tamilia M. Are solitary thyroid nodules more
likely to be malignant? J Otolaryngol Head Neck
Surg. 2012;41(2):119–23.
342. Sawka AM, Thephamongkhol K, Brouwers M,
Thabane L, Browman G, Gerstein HC. Clinical
review 170: a systematic review and metaanalysis
of the effectiveness of radioactive iodine remnant
ablation for well-differentiated thyroid cancer. J Clin
Endocrinol Metab. 2004;89:3668–76.
343. Bal C, Padhy AK, Panda S, Kumar L, Basu
AK.Insular carcinoma of thyroid. A subset of anaplastic thyroid malignancy with a less aggressive
clinical course. Clin Nucl Med. 1993;18:1056–8.
344. Bose SM, Ravindra N, Girdhar G, Bhattacharya
A. Clavicular metastasis of insular carcinoma of
the thyroid showing increased uptake in the presence of a functioning thyroid gland. Clin Nucl Med.
1998;23:774–5.
345. Begin LR, Allaire GS. Insular (poorly differentiated) carcinoma of the thyroid: an ultrastructural
and immuncytochemical study of two cases. J
Submicrosc Cytol Pathol. 1995;28:21–31.
346. Rosai J, Saxen EA, Woolner L. Undifferentiated
and poorly differentiated carcinoma. Semin Diagn
Pathol. 1985;2:123–36.
347. Doria R, Jekel JF, Cooper DL.Thyroid lymphoma.
The case for combined modality therapy. Cancer.
1994;73:200–6.
348. Compagno J, Oertel JE.Malignant lymphoma and
other lymphoproliferative disorders of the thyroid
gland. A clinicopathologic study of 245 cases. Am J
Clin Pathol. 1980;74:1–11.
349. Samaan NA, Ordonez NG. Uncommon types of
thyroid cancer. Endocrinol Metab Clin N Am.
1990;19:637–48.
350. Derringer GA, Thompson LD, Frommelt
RA, Bijwaard KE, Heffess CS, Abbondanzo
SL. Malignant lymphoma of the thyroid gland: a
clinicopathologic study of 108 cases. Am J Surg
Pathol. 2000;24:623–39.
351. Ansell SM, Grant CS, Habermann TM.Primary thyroid lymphoma. Semin Oncol. 1999;26:316–23.
352. Pasieka JL. Hashimoto’s disease and thyroid
lymphoma: role of the surgeon. World J Surg.
2000;24:966–70.
353. Thieblemont C, Mayer A, Dumontet C, Barbier Y,
Callet-Bauchu E, etal. Primary thyroid lymphoma
is a heterogeneous disease. J Clin Endocrinol Metab.
2002;87:105–11.
354. Holm LE, Blomgren H, Lowhagen T.Cancer risks
in patients with chronic lymphocytic thyroiditis. N
Engl J Med. 1985;312:601–4.
355. Kossev P, Livolsi V. Lymphoid lesions of the thyroid: review in light of the revised EuropeanAmerican lymphoma classication and upcoming
World Health Organization classication. Thyroid.
1999;9(12):1273–80.
356. Matsuzuka F, Miyauchi A, Katayama S, Narabayashi
I, Ikeda H, Kuma K, etal. Clinical aspects of primary
thyroid lymphoma: diagnosis and treatment based on
our experience of 119 cases. Thyroid. 1993;3:93–9.
357. Tupchong L, Hughes F, Harmer CL. Primary lymphoma of the thyroid: clinical features, prognostic
factors, and results of treatment. Int J Radiat Oncol
Biol Phys. 1986;12:1813–21.
358. Ishikawa H, Tamaki Y, Takahashi M, Higuchi K,
Sakaino K, Nonaka T, etal. Comparison of primary
thyroid lymphoma with anaplastic thyroid carcinoma on computed tomographic imaging. Radiat
Med. 2002;20(1):9–15.
359. Cha C, Chen H, Westra WH, Udelsman R.Primary
thyroid lymphoma: can the diagnosis be made
solely by ne-needle aspiration? Ann Surg Oncol.
2002;9:298–302.
360. Tsang RW, Gospodarowicz MK, Sutcliffe SB,
Sturgeon JF, Panzarella T, Patterson BJ. NonHodgkin’s lymphoma of the thyroid gland: prognostic factors and treatment outcome. The Princess
Margaret hospital lymphoma group. Int J Radiat
Oncol Biol Phys. 1993;27:599–604.
361. Fisher RI, Gaynor ER, Dahlberg S, Oken MM,
Grogan TM, Mize EM, et al. Comparison of a
standard regimen (CHOP) with three intensive che-
t.me/Dr_Mouayyad_AlbtousH
402
M. Sakr
motherapy regimens for advanced non-Hodgkin’s
lymphoma. N Engl J Med. 1993;328:1002–6.
362. Vigliotti A, Kong JS, Fuller LM, Velasquez
WS. Thyroid lymphomas stages IE and IIE:
comparative results for radiotherapy only, combination chemotherapy only, and multimodality treatment. Int J Radiat Oncol Biol Phys.
1986;12(10):1807–12.
363. DiBiase SJ, Grigsby PW, Guo C, Lin HS, Wasserman
TH.Outcome analysis for stage IE and IIE thyroid
lymphoma. Am J Clin Oncol. 2004;27:178–84.
364. Ha CS, Shadle KM, Medeiros LJ, Wilder RB, Hess
MA, Cabanillas F, et al. Localized non-Hodgkin
lymphoma involving the thyroid gland. Cancer.
2001;91:629–35.
365. Pyke CM, Grant CS, Habermann TM, Kurtin PJ, van
Heerden JA, Bergstralh EJ, et al. Non-Hodgkin’s
lymphoma of the thyroid: is more than biopsy necessary? World J Surg. 1992;16:604–9.
366. Klyachkin ML, Schwartz RW, Cibull M, Munn
RK, Regine WF, Kenady DE. Thyroid lymphoma: is there a role for surgery? Am Surg.
1998;64:234–8.
367. Harrington KJ, Michalaki VJ, Vini L, Nutting
CM, Syrigos KN, A’hern R, et al. Management
of non-Hodgkin’s lymphoma of the thyroid: the
Royal Marsden Hospital experience. Br J Radiol.
2005;78:405–10.
368. Sippel RS, Gauger PG, Angelos P, Thompson
NW, Mack E, Chen H. Palliative thyroidectomy
for malignant lymphoma of the thyroid. Ann Surg
Oncol. 2002;9:907–11.
369. Skarsgard ED, Connors JM, Robins RE.A current
analysis of primary lymphoma of the thyroid. Arch
Surg. 1991;126:1199–203.
370. Wirtzfeld DA, Winston JS, Hicks WL Jr, Loree
TR. Clinical presentation and treatment of nonHodgkin’s lymphoma of the thyroid gland. Ann Surg
Oncol. 2001;8:338–41.
371. Belal AA, Allam A, Kandil A, El Husseiny G,
Khafaga Y, Al Rajhi N, et al. Primary thyroid lymphoma: a retrospective analysis of prognostic factors
and treatment outcome for localized intermediate and high grade lymphoma. Am J Clin Oncol.
2001;24:299–305.
372. Laing RW, Hoskin P, Hudson BV, Hudson GV,
Harmer C, Bennett MH, et al. The signicance of
MALT histology in thyroid lymphoma: a review of
patients from the BNLI and Royal Marsden Hospital.
Clin Oncol (R Coll Radiol). 1994;6:300–4.
373. Willis RA.Metastatic tumours in the thyreoid gland.
Am J Pathol. 1931;7:187–208.
374. Cordes M, Kuwert T. Metastases of non-thyroidal
tumors to the thyroid gland: a regional survey in
middle Franconia. Exp Clin Endocrinol Diabetes.
2014;122:273–6.
375. Stevens TM, Richards AT, Bewtra C, Sharma
P. Tumors metastatic to thyroid neoplasms: a case
report and review of the literature. Pathol Res Int.
2011;23:86–93.
376. Nixon IJ, Whitcher M, Glick J, Palmer FL, Shaha
AR, Shah JP, et al. Surgical management of
metastases to the thyroid gland. Ann Surg Oncol.
2011;18:800–4.
377. Chung AY, Tran TB, Brumund KT, Weisman RA,
Bouvet M. Metastases to the thyroid: a review
of the literature from the last decade. Thyroid.
2012;22:258–68.
378. Chiumento C, Fiorentino A, Castaldo G, Fusco V.A
case of thyroid metastasis of nasopharyngeal cancer.
Tumori. 2011;97:24e–6e.
379. Rosen IB, Walsh PG, Bain J, Bedard YC.Secondary
malignancy of the thyroid gland and its management. Ann Surg Oncol. 1995;2:252–6.
380. Bae WK, Shim HJ, Choi YD, Kim JW, Cho SH,
Kang HC, etal. Severe hypothyroidism induced by
thyroid metastasis of cholangiocarcinoma. Cancer
Res Treat. 2009;41:56–8.
381. Basu S, Alavi A.Metastatic malignant melanoma to
the thyroid gland detected by FDG-PET imaging.
Clin Nucl Med. 2007;32:388–9.
382. Delitala AP, Vidili G, Manca A, Dial U, Delitala
G, Fanciulli G. A case of thyroid metastasis from
pancreatic cancer: case report and literature review.
BMC Endocr Disord. 2014;14:6–9.
383. Gherardi G, Scherini P, Ambrosi S.Occult thyroid
metastasis from untreated uveal melanoma. Arch
Ophthalmol. 1985;103:689–91.
384. De Ridder M, Sermeus AB, Urbain D, Storme
GA.Metastases to the thyroid gland—a report of six
cases. Eur J Intern Med. 2003;14:377–9.
385. Demir L, Erten C, Somali I, Can A, Dirican A,
Bayoglu V, etal. Metastases of renal cell carcinoma
to the larynx and thyroid: two case reports on metastasis developing years after nephrectomy. Can Urol
Assoc J. 2012;6:E209–12.
386. Lam KY, Lo CY. Metastatic tumors of the thyroid
gland: a study of 79 cases in Chinese patients. Arch
Pathol Lab Med. 1998;122(1):37–41.
387. Papi G, Fadda G, Corsello SM, Corrado S, Rossi
ED, Radighieri E, et al. Metastases to the thyroid
gland: prevalence, clinicopathological aspects and
prognosis: a 10-year experience. Clin Endocrinol.
2007;66:565–71.
388. Shimaoka K. Thyrotoxicosis due to metastatic
involvement of the thyroid. Arch Intern Med.
1980;140:284–5.
389. Peparini N, Di Matteo FM, Maturo A, Marzullo A,
Campana FP.Unusual metastasis of gastrointestinal
stromal tumor misdiagnosed as anaplastic thyroid
carcinoma. Int J Surg. 2008;6:415–7.
390. Cozzolino I, Malapelle U, Carlomagno C, Palombini
L, Troncone G. Metastasis of colon cancer to the
thyroid gland: a case diagnosed on ne-needle aspirate by a combined cytological, immunocytochemical, and molecular approach. Diagn Cytopathol.
2010;38:932–5.
391. Mattavelli F, Collini P, Gervasoni C, Pizzi N, Pallotti
F, Pastorino U.Double, metachronous thyroid metastases of colon cancer. Tumori. 2006;92:249–51.
t.me/Dr_Mouayyad_AlbtousH
13 Malignant Thyroid Disease
403
392. Shah DJ, Dronca RS. Latest advances in chemotherapeutic, targeted, and immune approaches in the
treatment of metastatic melanoma. Mayo Clin Proc.
2014;89:504–19.
393. Burt A, Goudie RB. Diagnosis of primary thyroid
carcinoma by immunohistological demonstration of
thyroglobulin. Histopathology. 1979;3:279–86.
394. Katsuya Y, Yoshida A, Watanabe S, Tsuta
K. Tumour- to- tumour metastasis from papillary
thyroid carcinoma with BRAF mutation to lung
adenocarcinoma with EGFR mutation: the utility
of mutation-specic antibodies. Histopathology.
2015;67:262–6.
395. Hurlimann J, Gardiol D, Scazziga
B. Immunohistology of anaplastic thyroid carcinoma. A study of 43 cases. Histopathology.
1987;11:567–80.
396. Wood K, Vini L, Harmer C.Metastases to the thyroid gland: the Royal Marsden experience. Eur J
Surg Oncol. 2004;30:583–8.
397. Cichon S, Anielski R, Konturek A, Barczynski M,
Cichon W. Metastases to the thyroid gland: seventeen cases operated on in a single clinical center.
Langenbeck's Arch Surg. 2006;391:581–7.
398. Czech JM, Lichtor TR, Carney JA, van Heerden
JA.Neoplasms metastatic to the thyroid gland. Surg
Gynecol Obstet. 1982;155:503–5.
399. Ericsson M, Biorklund A, Cederquist E,
Ingemansson S, Akerman M.Surgical treatment of
metastatic disease in the thyroid gland. J Surg Oncol.
1981;17:15–23.
400. Russell JO, Yan K, Burkey B, Scharpf J.Nonthyroid
metastasis to the Thyroid gland: case series and
review with observations by primary pathology.
Otolaryngol Head Neck Surg. 2016;155(6):961–8.
401. Ishikawa M, Hirano S, Tsuji T, Ito J.Management of
metastasis to the thyroid gland. Auris Nasus Larynx.
2011;38:426–30.
402. Kumamoto K, Utsumi Y, Sugano K, Hoshino M,
Suzuki S, Takenoshita S. Colon carcinoma metastasis to the thyroid gland: report of a case with a
review of the literature. Tumori. 2006;92:252–6.
403. Thelen A, Jonas S, Benckert C, Lopez-Hänninen E,
Rudolph B, Neumann U, et al. Liver resection for
metastases from renal cell carcinoma. World J Surg.
2007;31:802–7.
404. Kjaer M, Frederiksen PL, Engelholm
SA. Postoperative radiotherapy in stage II and III
renal adenocarcinoma. A randomized trial by the
Copenhagen renal cancer study group. Int J Radiat
Oncol Biol Phys. 1987;13:665–72.
405. Iesalnieks I, Winter H, Bareck E, Sotiropoulos
GC, Goretzki PE, Klinkhammer-Schalke M,
et al. Thyroid metastases of renal cell carcinoma:
clinical course in 45 patients undergoing surgery.
Assessment of factors affecting patients’ survival.
Thyroid. 2008;18:615–24.
406. Chen H, Nicol TL, Udelsman R.Clinically signicant, isolated metastatic disease to the thyroid gland.
World J Surg. 1999;23:177–80.
407. McCabe DP, Farrar WB, Petkov TM, Finkelmeier W,
O’Dwyer P, James A. Clinical and pathologic correlations in disease metastatic to the thyroid gland.
Am J Surg. 1985;150:519–23.
408. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P,
Burt ME, Brady MS.Resection of metastatic renal
cell carcinoma. J Clin Oncol. 1998;16:2261–6.
409. Maldazys JD, deKernion JB.Prognostic factors in
metastatic renal carcinoma. J Urol. 1986;136:376–9.
410. Rabinovitch RA, Zelefsky MJ, Gaynor JJ, Fuks
Z. Patterns of failure following surgical resection
of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol.
1994;12:206–12.
411. Ljungberg B, Bensalah K, Caneld S, Dabestani
S, Hofmann F, Hora M, et al. EAU guidelines
on renal cell carcinoma: 2014 update. Eur Urol.
2015;67:913–24.
412. Salah S, Tanvetyanon T, Abbasi S.Metastatectomy
for extra-cranial extra-adrenal non–small cell
lung cancer solitary metastases: systematic review
and analysis of reported cases. Lung Cancer.
2012;75:9–14.
413. Lievre A, Leboulleux S, Boige V, et al. Thyroid
metastases from colorectal cancer: the Institut
Gustave Roussy experience. Eur J Cancer.
2006;42:1756–9.
414. Shimaoka K, Sokal JE, Pickren JW.Metastatic neoplasms in the thyroid gland. Pathological and clinical ndings. Cancer. 1962;15:557–65.
415. Nakhjavani MK, Gharib H, Goellner JR, van
Heerden JA. Metastasis to the thyroid gland. A
report of 43 cases. Cancer. 1997;79(5):74–578.
416. Kim TY, Kim WB, Gong G, Hong SJ, Shong
YK. Metastasis to the thyroid diagnosed by
ne-needle aspiration biopsy. Clin Endocrinol.
2005;62:236–41.
417. Heffess CS, Wenig BM, Thompson LD.Metastatic
renal cell carcinoma to the thyroid gland: a
clinicopathologic study of 36 cases. Cancer.
2002;95:1869–78.
418. Leeper RD. The effect of
131
I therapy on survival
of patients with metastatic papillary or follicular thyroid carcinoma. J Clin Endocrinol Metab.
1973;36:1143–52.
419. Beierwaltes WH, Nishiyama RH, Thompson NW,
Copp JE, Kubo A.Survival time and “cure” in papillary and follicular thyroid carcinoma with distant metastases: statistics following University of
Michigan therapy. J Nucl Med. 1982;23:561–8.
420. Bernier MO, Leenhardt L, Hoang C, Aurengo A,
Mary JY, Menegaux F, etal. Survival and therapeutic modalities in patients with bone metastases of
differentiated thyroid carcinomas. J Clin Endocrinol
Metab. 2001;86:1568–73.
421. Sampson E, Brierley JD, Le LW, Rotstein L, Tsang
RW.Clinical management and outcome of papillary
and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer.
2007;110:1451–6.
t.me/Dr_Mouayyad_AlbtousH
404
M. Sakr
422. Durante C, Haddy N, Baudin E, Leboulleux S,
Hartl D, Travagli JP, etal. Long-term outcome of
444 patients with distant metastases from papillary
and follicular thyroid carcinoma: benets and limits of radioiodine therapy. J Clin Endocrinol Metab.
2006;91:2892–9.
423. Dupuy DE, Monchik JM, Decrea C, Pisharodi
L. Radiofrequency ablation of regional recurrence from well-differentiated thyroid malignancy.
Surgery. 2001;130:971–7.
424. Lewis BD, Hay ID, Charboneau JW, McIver B,
Reading CC, Goellner JR. Percutaneous ethanol injection for treatment of cervical lymph node
metastases in patients with papillary thyroid carcinoma. AJR Am J Roentgenol. 2002;178:699–704.
425. Eustatia-Rutten CF, Romijn JA, Guijt MJ, Vielvoye
GJ, van den Berg R, Corssmit EP, Pereira AM, Smit
JW. Outcome of palliative embolization of bone
metastases in differentiated thyroid carcinoma. J
Clin Endocrinol Metab. 2003;88:3184–9.
426. Ronga G, Filesi M, Montesano T, Di Nicola
AD, Pace C, Travascio L, et al. Lung metastases from differentiated thyroid carcinoma. A 40
years’ experience. Q J Nucl Med Mol Imaging.
2004;48:12–9.
427. Lin JD, Chao TC, Chou SC, Hsueh C. Papillary
thyroid carcinomas with lung metastases. Thyroid.
2004;14:1091–6.
428. Shoup M, Stojadinovic A, Nissan A, Ghossein
RA, Freedman S, Brennan MF, Shah JP, Shaha
AR. Prognostic indicators of outcomes in patients
with distant metastases from differentiated thyroid
carcinoma. J Am Coll Surg. 2003;197:191–7.
429. Zettinig G, Fueger BJ, Passler C, Kaserer K, Pirich
C, Dudczak R, Niederle B.Long-term follow-up of
patients with bone metastases from differentiated
thyroid carcinoma—surgery or conventional therapy? Clin Endocrinol. 2002;56:377–82.
430. Pittas AG, Adler M, Fazzari M, Tickoo S, Rosai J,
Larson SM, Robbins RJ.Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients.
Thyroid. 2000;10:261–8.
431. Dinneen SF, Valimaki MJ, Bergstralh EJ, Goellner
JR, Gorman CA, Hay ID. Distant metastases in
papillary thyroid carcinoma: 100 cases observed at
one institution during 5 decades. J Clin Endocrinol
Metab. 1995;80:2041–5.
432. Foote RL, Brown PD, Garces YI, McIver B,
Kasperbauer JL.Is there a role for radiation therapy
in the management of Hürthle cell carcinoma? Int J
Radiat Oncol Biol Phys. 2003;56:1067–72.
433. Pak H, Gourgiotis L, Chang WI, Guthrie LC,
Skarulis MC, Reynolds JC, etal. Role of metastasectomy in the management of thyroid carcinoma:
the NIH experience. J Surg Oncol. 2003;82:10–8.
434. Vitale G, Fonderico F, Martignetti A, Caraglia
M, Ciccarelli A, Nuzzo V, Abbruzzese A, Lupoli
G. Pamidronate improves the quality of life
and induces clinical remission of bone metastases in patients with thyroid cancer. Br J Cancer.
2001;84:1586–90.
435. Kitamura Y, Shimizu K, Nagahama M, Sugino
K, Ozaki O, Mimura T, Ito K, Ito K, Tanaka
S.Immediate causes of death in thyroid carcinoma:
clinicopathological analysis of 161 fatal cases. J Clin
Endocrinol Metab. 1999;84:4043–9.
436. Brose MS, Smit J, Capdevila J, Elisei R, Nutting
C, Pitoia F, Robinson B, Schlumberger M, Shong
YK, Takami H.Regional approaches to the management of patients with advanced, radioactive iodinerefractory differentiated thyroid carcinoma. Expert
Rev Anticancer Ther. 2012;12:1137–47.
437. Sabra MM, Dominguez JM, Grewal RK, Larson
SM, Ghossein RA, Tuttle RM, Fagin JA. Clinical
outcomes and molecular prole of differentiated
thyroid cancers with radioiodine-avid distant metastases. J Clin Endocrinol Metab. 2013;98:E829–36.
438. Benua RS, Cicale NR, Sonenberg M, Rawson
RW.The relation of radioiodine dosimetry to results
and complications in the treatment of metastatic
thyroid cancer. Am J Roentgenol Radium Ther Nucl
Med. 1962;87:171–82.
439. Chiu AC, Delpassand ES, Sherman SI. Prognosis
and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab. 1997;82:3637–42.
440. Henriques de Figueiredo B, Godbert Y, Soubeyran
I, Carrat X, Lagarde P, etal. Brain metastases from
thyroid carcinoma: a retrospective study of 21
patients. Thyroid. 2014;24:270–6.
441. Nose V. Familial thyroid cancer: a review. Mod
Pathol. 2011;24(Suppl. 2):S19–33.
442. Sipos JA, Mazzaferri EL. The therapeutic management of differentiated thyroid cancer. Expert Opin
Pharmacother. 2008;9(15):2627–37.
443. Chiefari E, Russo D, Giuffrida D, Zampa GA,
Meringolo D, Arturi F, et al. Analysis of RET
proto- oncogene abnormalities in patients with
MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma. J Endocrinol Investig.
1998;21(6):358–64.
444. Khan A, Smellie J, Nutting C, Harrington
K, Newbold K. Familial nonmedullary thyroid cancer: a review of the genetics. Thyroid.
2010;20(7):795–801.
445. Zoeller RT.Transplacental thyroxine and fetal brain
development. J Clin Invest. 2003;111(7):954–7.
446. Kimura T, Van Keymeulen A, Golstein J, Fusco
A, Dumont JE, Roger PP. Regulation of thyroid cell proliferation by TSH and other factors: a
critical evaluation of invitro models. Endocr Rev.
2001;22(5):631–56.
447. Soares P, Trovisco V, Rocha AS, Lima J, Castro P,
Preto A, etal. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.Oncogene. 2003;22(29):4578–80.
t.me/Dr_Mouayyad_AlbtousH
Соседние файлы в папке Библиотека им академика М.И. Перельмана